Has Mitchell Humphreys, MD received payments from drug or device companies?

Yes. Drug and device makers reported $357,924 in general payments to Mitchell Humphreys, MD across 161 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mitchell Humphreys, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mitchell Humphreys, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mitchell Humphreys, MD

Urology · Phoenix, AZNPI 1144208430

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $274,134 of the $357,924 with a category attached, or 76.6%. Johnson & Johnson accounts for 73.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $235,813 and has fallen 84.8% since, to $35,758 in 2025. Among urology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$357,924in general payments, 2019–2025

Across 161 payments — averaging $2223.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$262K
Boston Scientific$56K
Gyrus ACMI, Inc.$20K
Lumenis, Inc$11K
Olympus Corporation Of The Americas$4K
Medical Device Business Services, Inc.$2K
plus $2K from 10 others

$789,094in research payments, 2019–2025

Across 70 payments — averaging $11,273 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Boston Scientific$445K
KARL Storz Endoscopy-america$153K
Gyrus ACMI, Inc.$123K
Procept Biorobotics Corporation$44K
Olympus Corporation Of The Americas$24K
Urogen Pharma, Inc.$352

What the payments were for

Consulting fees$68,80319%
Speaking & faculty fees$274,13477%
Travel & lodging$8,9983%
Food & beverage$5,9892%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	33	$262,322
Boston Scientific	79	$56,113
Gyrus ACMI, Inc.	16	$20,447
Lumenis, Inc	3	$10,500
Olympus Corporation Of The Americas	2	$4,435
Medical Device Business Services, Inc.	12	$2,011
Urogen Pharma, Inc.	3	$500
Dornier Medtech America, Inc	1	$491
Coloplast	5	$396
KARL Storz Endoscopy-america	1	$215
Axonics, Inc.	1	$140
Olympus America Inc.	1	$133
Innovation Technologies Inc	1	$116
Richard Wolf Medical Instruments Corp.	1	$44
Auris Health, Inc.	1	$41
Procept Biorobotics Corporation	1	$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$357,924 in reported general payments places this provider in the 95th percentile of 269 urology providers in Arizona.

See all urology providers in Arizona →

Medicare billing

Part B allowed, 2024

$1,220,018

Medicare patients

910

Services billed

7,861

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other urology in Phoenix

Daniel JaffeePhoenix$280K
Donald LammPhoenix$80K
Karen SternPhoenix$54K
Ali BorhanPhoenix$42K
Premal DesaiPhoenix$33K
Yoon HongPhoenix$18K
Amar PatelPhoenix$18K
Scott KalinowskiPhoenix$14K
Elizabeth TourvillePhoenix$14K
Jack AndrewsPhoenix$13K

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →